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remains unanswered. The aim of the study was to 
retrospectively review the changes in total testosterone in 
low risk prostate cancer patients treated with IMRT alone, in 
comparison with a RP cohort and to assess the correlation 
between dosimetric parameters for the testes and changes in 
the level of testosterone. 
 
Material and Methods: From 2009-2012 we studied 115 men 
in this cross-sectional study. 92 patients underwent RP and 
23 patients were treated with IMRT exclusively. The patients 
were treated with IMRT to the prostate and seminal vesicles 
for a total dose of 76 Gy (2 Gy/d, 5d/w) with 6 MV photons. 
We measured serum levels of total testosterone, at baseline 
and at 3, 12 and 24 months (m) after treatment. We 
calculated the mean and maximum dose in the testes and the 
distance between PTV-testes. T –test and Pearson correlation 
index (PI) were used for statistical purposes. 
 
Results: Patients undergoing RP were younger with IMRT 
(64.3 vs 72 years, p<0.0001). No differences regarding serum 
hormonal levels were found at baseline between the two 
groups. At 3months the testosterone levels were significantly 
lower in IMRT group (360,3 vs 414,83 ng/dl) in comparison 
with RP group (p <0,039). At 12 months testosterone levels 
remained significantly lower (339,89 vs 402,39 ng/dl, p 0,03) 
in the IMRT group. 
In the IMRT group the mean and maximum testes doses (± SD) 
were 0.472Gy (±0.195) and 0.896 Gy (±0.382) respectively. At 
3 months, the mean testosterone reduction was 29.4 ng/dl (± 
111.3), without correlation among the mean and maximum 
dose to the testes (p=0.2). At 12 months, 60% (12/20) of the 
patients had recovered their basal testosterone levels as well 
as 61% (11/18) at 24 months. The PI didn´t show any 
statistical significance related with testosterone kinetics and 
dosimetric parameters at 12 and 24 months. In the 
multivariate analyses, we didn´t find any significant 
relationship regarding: scattered doses in testes; total dose 
to the prostate; distance between PTV-testes or age, with 
testosterone recovery. 
 
Conclusion: Despite IMRT for localized prostate cancer 
leading to low doses to the testes, we observed a decline in 
total testosterone higher than RP. Nevertheless, it doesn´t 
seem to correlate with either dosimetric parameters or the 
scattered dose in testes. More studies are needed to 
elucidate the role that the prostate may play as an endocrine 
organ itself. 
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Purpose or Objective: To investigate the correlation 
between initial prostate volume and the probability of 
developing acute Obstructive Voiding Symptoms (OVS) during 
the course of moderate hypofractionated (HF) prostate RT. 
 
Material and Methods: Data from patients (n=181) 
undergoing IMRT delivered, daily Cone Beam CT guided, HF 
RT were retrospectively analyzed. Two treatment schedules 
were considered: HF1 (2.6 Gy/fr, 27 fr; n=107) and HF2 (3.15 
Gy/fr, 20 fr, 4 days a week; n=74). Patients verifying: 1. 
previous OVS score 3 or greater according the International 
Prostatic Symptoms Score (IPSS), 2. CTVs encompassing 
volume outside the prostatic capsule (i.e. margin for 
extracapsular extension or seminal vesicles invasion), 3. 
presence of central calcification masses or 4. altered RT 
schedules for reasons other than OVS, were excluded. 
Measured HF1 and HF2 median prostate volumes as contoured 
in the simulation CT image were 61.0 cc [18.6, 157.7] and 
53.6 cc [18.5, 114.8], respectively. OVS was assessed 
according the RTOG/CTC v3.0 scale. Development of OVS G2 
or greater during treatment was considered as binary end-
point. Volume-effect correlation was evaluated by logit 
analysis, assuming a log-normal distribution. 
 
Results: OVS G2 or greater was found in HF1 (n=11) and HF2 
(n=10) patients. A few patients HF1 (n=1) and HF2 (n=5) 
needed urethral catheterization. Some patients (n=12) had 
their course of treatment modified due to OVS: temporary 
interruption of treatment (n=6), modified fractionation (n=5), 
urinary catheterization at treatment delivery (n=1). Logit 
analysis showed that prostate volume did not correlate with 
OVS for HF1 patients (p > 0.05) but proved to be significantly 
predictive of OVS for HF2 patients (p = 0.0002). For this 
second arm, normalized gradient of the volume-effect 
regression curve was found to be γ50=7.8 [3.2-14.7] and 
ED50% = 95.7 cc [84.7-117.8] (see Figure). The Receiver 
Operating Characteristics analysis (ROC) showed excellent 
predictive capabilities of the model, with Area Under the 
Curve AUC=0.94. Based on these findings, a volume cutoff 
value of 80 cc, corresponding to an acceptable 20% risk of 
OVS G2 or greater was selected. 
 
 
 
Conclusion: Depending on the HF scheme, patients with 
larger prostate volume will face an increasing risk of OVS. 
This may compromise their quality of life and alter the RT 
treatment schedule. In this work, we successfully correlated 
OVS to prostate volume. This predictive model can be 
exploited for decision-making prior to treatment. In our 
Institution, patients with prostate volume larger than 80 cc 
will be preferably addressed to the HF1 schedule due to the 
risk of OVS. 
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Purpose or Objective: Comorbidity assessment is essential to 
triage of care for men with prostate cancer. Specially in 
these with an expectative of life less of ten years. We made 
a Spanish validation of comorbid revised Charlson index (RCI) 
applied to prostate cancer.  
 
Material and Methods: A group of 619 consecutive patients 
of Prostate Cancer diagnosed between 1994- 2007 were send 
for clinical assessment at Radiation Oncology Department of 
Hospital Clinic of Bacelona. 
A long the period of follow-up ( till November 2014) 69 
patients deceased for Prostate Cancer and were excluded in 
this study in order to determine the risks of mortality 
associated with comorbidities measured by the RCI. 
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RCI was classified in three categories 0 to 2 , 3 to 4 and 5 and 
higher. For this purpose we used Kaplan-Meier method and 
Cox proportional hazards modeling 
 
Results: Finally 550 patients with prostate cancer were 
included, with median age of 70 years old (47-85), Mean 
follow-up time was 136.8 months, between 5,6 and 245,8 
months. D’Amico risk classification distribution was for low 
risk, mediun and high 20.4%, 36,5% and 43,1% respectively. 
RCI distribution categories was as follows 61,5%, 21,8 and 
16,7%. Survival analysis showed significant differences 
(p<0.001) between RCI groups at 5 and 10 years. Survival 
probability was 98,2 and 88,5% ; 95% and 79,6% ; and 52,2% 
and 8,9% was respectively for each RCI category. 
 
Conclusion: RCI allowed for more accurate identification of 
men at highest risk for other cause mortality. 
Our results are in concordance with original RCI .This revised 
index may be used to aid medical decision making and 
personalized medecine for men with prostate cancer.  
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Purpose or Objective: The definition of the clinical target 
volume (CTV) for salvage radiotherapy after prostatectomy is 
based on clinical and pathologic variables of the tumor and 
consensus guidelines. Multiparametric-MRI is recommended 
to evaluate pelvic recurrences after radical prostatectomy 
when the PSA is low (0.2-2 ng/ml) but the benefit of planning 
individualised radiation treatment based on the results of MRI 
is unknown. We analysed whether all suspicious lesions 
detected with pelvic multiparametric MRI were included in 
the clinical target volume defined according to four current 
guidelines and we determined the percentage of missing 
target if this radiological information was lost. 
 
Material and Methods: We retrospectively reviewed the 
clinical records and multiparametric MRI studies of 70 
patients with PSA recurrence after radical prostatectomy. 
Salvage radiotherapy of at least the prostate bed was 
indicated in all cases. On the simulation CT scan of 33 
patients who had visible tumor recurrence in the MRI study, 
we delineated four different CTV according to RTOG, EORTC, 
PMH and FROGG consensus guidelines for postoperative 
prostate bed irradiation. We delineated a relapse CTV which 
included the radiological tumor recurrence plus 5 mm. For 
the PTV, we added a 5 mm margin. We compared volume size 
of the CTV and determined the percentage of geographically 
missed target (relapse PTV not included / relapse PTV).  
 
Results: Multiparametric-MRI was positive in 33/70 patients. 
Local recurrence occurred in 27 patients, mainly in the 
perianastomotic area (19). Mutiparametric-MRI detected 
positive lymph nodes in 7 patients, mostly in the external 
iliac region. The mean size of the lymph nodes was 10 mm 
(range 8-16 mm). The mean volumes of the CTV delineated 
according to the EORTC, RTOG, PMH and FROGG consensus 
were 81.5, 100.7, 109.3 and 99.7 cc, respectively. In 2 out of 
33 cases, the recurrence depicted in the pelvic MRI was not 
totally enclosed in the CTV, independently of the consensus 
guidelines used. The missed recurrences were located in the 
left retrovesical region (patient 1) and at the level of the 
penile bulb (patient 2) . The volumes of the relapsed PTV 
were 23.4 and 14.9 cc, respectively. The percentages of 
relapse PTV out of the PTV created according to each 
guideline were 41%, 59%, 44 and 44% in patient 1 and 44%, 
39%, 39% and 41% in patient 2. In 7 out of 70 patients (10%), 
lymph node recurrence would have been missed if we had 
only considered salvage prostate bed irradiation.  
 
Conclusion: Using current guidelines for CTV definition for 
salvage radiotherapy after prostatectomy, we found that the 
local recurrences depicted in the pelvic multiparametric MRI 
were totally covered in most patients. Multiparametric-MRI 
may help tailor local and lymph node CTV and identify lesions 
to treat with a higher dose 
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Purpose or Objective: To report the toxicity and preliminary 
biochemical outcomes with high-dose intensity-modulated 
radiation therapy (IMRT) to a dose of 82.8Gy in patients 
prostate cancer. 
 
Material and Methods: Between April 2002 and December 
2013, 757 patients with biopsy proven prostate cancer were 
treated with high-dose IMRT. While 398 patients received a 7 
or 8- field -IMRT -sliding window- technique up to a median 
total dose to the prostate of 77.4 Gy/1.8Gy, 359 patients 
were treated with a 2 arc-Volumetric Modulated ArcTherapy 
(VMAT) plans up to a median total dose to the prostate of 
82.0Gy/ 1.8Gy. In 264 high-risk prostate cancer patients the 
pelvic node region was treated to incorporate the nodes at 
risk. Total doses of 50.4Gy were prescribed to the pelvis. In 
29 % of SW patients and 23% of VMAT patients an additional 
boost of 5 to 16Gy was administered in cases of MRI-staged 
lymph node metastases. Acute and late toxicities were 
prospectively scored by the RTOG/ LENT SOMA morbidity 
grading scales (until 2009) and a modified CTCAEv3.0 score 
(since 2009), respectively. Biochemical failure was defined 
according to the Phoenix definition of nadir + 2ng/ml. The 
median follow- up time was 65 months (range,12-151 
months). 
 
Results: The IMRT dose distribution provided excellent PTV 
coverage and satisfying protection of all the organs at risk, 
with less than 2% of all patients experiencing grade (G) 3 
toxicities, G4 toxicities were not observed at all. In total 40.3 
/ 11 / 1.1% of patients developed acute G1/ 2/ 3 
genitourinary (GU) toxicities. 28%/ 3.1% of patients 
experienced acute G1/ 2 gastrointestinal (GI) side effects, no 
patient developed acute > G2 gastrointestinal symptoms. 
Late GU- and GI toxicity was mild with > 85% of the patients 
free from any GU/GI toxicity during follow-up and no time 
trend to increased rates or to higher grade of GU/GI- 
toxicity. Maximum late GU toxicities were G1/ 2/ 3 for 10/ 
2.5/ 1.6% of patients, respectively. Maximum late GI 
toxicities were G1/2 for 4.9 / 0.4%of patients. The 5-year 
freedom from biochemical failure (FFBF) was 87.8%for all 
patients and 95, 79.9 and 83.4% for low-, intermediate-, and 
high-risk disease. 
 
Conclusion: These data demonstrate that escalated -dose 
IMRT is a well tolerated technique in prostate cancer patients 
and the preliminary excellent biochemical control rates are 
encouraging.  
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